1. Home
  2. SDGR vs CMPX Comparison

SDGR vs CMPX Comparison

Compare SDGR & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$12.15

Market Cap

925.8M

Sector

Health Care

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$1.81

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDGR
CMPX
Founded
1990
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
925.8M
927.5M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
SDGR
CMPX
Price
$12.15
$1.81
Analyst Decision
Buy
Strong Buy
Analyst Count
9
9
Target Price
$21.00
$14.57
AVG Volume (30 Days)
1.4M
12.2M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
45.14
N/A
EPS
N/A
N/A
Revenue
$255,869,000.00
N/A
Revenue This Year
$0.76
N/A
Revenue Next Year
$4.60
$934.41
P/E Ratio
N/A
N/A
Revenue Growth
23.29
N/A
52 Week Low
$10.95
$1.61
52 Week High
$27.63
$6.88

Technical Indicators

Market Signals
Indicator
SDGR
CMPX
Relative Strength Index (RSI) 47.21 26.23
Support Level $11.18 $1.61
Resistance Level $13.36 $3.54
Average True Range (ATR) 0.65 0.15
MACD -0.06 0.06
Stochastic Oscillator 32.53 46.05

Price Performance

Historical Comparison
SDGR
CMPX

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: